«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

27卷

期数:

2021年05期

页码:

515-519

栏目:

临床医学

出版日期:

2021-09-10

文章信息/Info

Title:

The expression and clinical significance of Pentraxin 3 in breast cancer

文章编号:

1006-8147(2021)05-0515-05

作者:

贾圣陶¹; 赵雅雯¹; 王克朕¹; 张慧鲲¹; 谷峰²; 马勇杰¹

（天津医科大学肿瘤医院1.肿瘤细胞生物学实验室，2.乳腺病理科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，乳腺癌防治教育部重点实验室，天津市恶性肿瘤临床医学研究中心，天津³000⁶0）

Author(s):

JIA Sheng-tao¹; ZHAO Ya-wen¹; WANG Ke-zhen¹; ZHANG Hui-kun¹; GU Feng²; MA Yong-jie¹

（1.Laboratory of Tumor Cell Biology，2.Department of Breast Pathology，Tianjin Medical University Cancer Institute and Hospital ,National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tian jin，Key Laboratory of Breast C

关键词:

乳腺癌; PTX3; 表达

Keywords:

breast cancer; PTX3; expression

分类号:

R737.9

DOI:

-

文献标志码:

A

摘要:

目的：探究炎症因子五聚蛋白3（Pentraxin3，PTX3）在乳腺癌中的表达及其临床意义。方法：选取2004—2012年的309例乳腺浸润性导管癌（IDC）患者乳腺癌组织以及33例癌旁组织石蜡标本，通过免疫组织化学染色分析PTX3蛋白在乳腺癌中的表达。结果：PTX3蛋白在乳腺癌组织中较癌旁表达更高（χ2 =35.3，P<0.001），其表达水平与肿瘤的组织学级别呈正相关（r=0.139，P<0.05）；Kaplan-Meier生存分析表明，PTX3蛋白是乳腺癌患者总生存（χ2 =5.708，P<0.05）及无进展生存（χ2 =4.958，P<0.05）的独立预后因素，PTX3高表达的乳腺癌患者预后更差。结论：PTX3蛋白在乳腺癌中高表达，且与乳腺癌的组织学级别呈正相关，PTX3高表达的患者预后差，PTX3可以作为乳腺癌精准治疗的潜在靶标。

Abstract:

Objective: To explore the expression and clinical significance of inflammatory factor Pentraxin 3 （PTX3） in breast cancer. Methods: A total of 309 breast cancer tissues from breast invasive ductal carcinoma （IDC） patients and 33 adjacent normal tissues paraffin specimens ranged from 2004 to 2012 were selected. The expression of PTX3 in breast cancer were analyzed by immunohistochemical staining. Results: Analysis of clinical samples showed that the expression of PTX3 in breast cancer tissues was higher than that in adjacent normal tissues（χ2=35.3，P<0.001） and its expression level was positively correlated with the histological grade of breast cancer（r=0.139，P<0.05）. Kaplan-Meier survival analysis showed that the protein level of PTX3 was an independent predictor of overall survival（χ2 =5.708，P<0.05） and progression-free survival（χ2 =4.958，P<0.05） in patients with breast cancer. Breast cancer patients with higher PTX3 expression had a worse prognosis. Conclusion: PTX3 protein is highly expressed in breast cancer and is positively correlated with the histological grade of breast cancer. Patients with high level of PTX3 have poor prognosis. PTX3 can be used as a potential target for precise breast cancer treatment.

参考文献/References:

[1] MANTOVANI A，ALLAVENA P，SICA A，et al. Cancer-related inflammation[J]. Nature，2008，454（7203）：436
[2] GRETEN F R，GRIVENNIKOV S I. Inflammation and cancer：triggers，mechanisms，and consequences[J]. Immunity，2019，51（1）：27
[3] ERRENI M，MANFREDI A A，GARLANDA C，et al. The long pentraxin PTX3：a prototypical sensor of tissue injury and a regulator of homeostasis[J]. Immunol Rev，2017，280（1SI）：112
[4] FORNAI F，CARRIZZO A，FORTE M，et al. The inflammatory protein Pentraxin 3 in cardiovascular disease[J]. Immun Ageing，2016， 13（1）：25
[5] LIU C，YAO Y，WANG W. Pentraxin-3 as a prognostic marker in patients with small-cell lung cancer[J]. Med Oncol，2014，31（10）：207
[6] YING T，LEE C，CHIOU H，et al. Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells[J]. Sci Rep，2016，6（29385）：doi： 10.1038/srep29385
[7] CHOI B，LEE E J，SHIN M K，et al. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3[J]. Oncotarget，2016，7（34）：55506
[8] RATHORE M，GIRARD C，OHANNA M，et al. Cancer cell-derived long pentraxin 3（PTX3） promotes melanoma migration through a toll-like receptor 4（TLR4）/NF-κB signaling pathway[J]. Oncogene，2019，38（30）：5873
[9] GARLANDA C，BOTTAZZI B，MAGRINI E，et al.PTX3，a humoral pattern recognition molecule，in innate immunity，tissue repair，and cancer[J].Physiol Rev，2018，98（2）：623
[10] Veletic I，Manshouri T，Newberry K J，et al. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis[J]. Br J Haematol，2019，185（2）： 382
[11] MAHVI D A，LIU R，GRINSTAFF M W，et al. Local cancer recurrence： the realities，challenges，and opportunities for new therapies[J]. CA Cancer J Clin，2018，68（6）：488
[12] CHOI B，LEE E J，SONG D H，et al. Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function[J]. Oncotarget，2014，5（2）：481
[13] ZHANG P，LIU Y，LIAN C，et al. SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation[J]. Nat Commun，2020，11（1）： 2487
[14] KAMPO S，AHMMED B，ZHOU T，et al. Scorpion venom analgesic peptide，bmK AGAP tnhibits stemness，and epithelial-mesenchymal transition by down-regulating PTX3 in breast cancer[J]. Front Oncol，2019，9（21）：doi：10.3389/fonc.2019.00021
[15] THOMAS C，HENRY W，CUIFFO B G，et al. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers[J]. Sci Signal，2017，10（467）：eaah4674
[16] SCIMECA M，ANTONACCI C，COLOMBO D，et al. Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers[J]. Tumour Biol，2016，37（4）：5427
[17] VAN NETTEN J P，CANN S H，THORNTON I G，et al. The lymphatics in infiltrating ductal carcinoma （IDC） of the breast[J]. Cancer Treat Rev，2018，62：97
[18] DONI A，STRAVALACI M，INFORZATO A，et al. The long pentraxin PTX3 as a link between innate immunity，tissue remodeling，and cancer[J]. Front Immunol，2019，10：712.
[19] CHANG W，WU S，HUANG W，et al. PTX3 gene activation in EGF-induced head and neck cancer cell metastasis[J]. Oncotarget，2015， 6（10）：7741
[20] TUNG J N，KO C P，YANG S F，et al. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo[J]. J Neurooncol，2016，129（2）：201
[21] LIU Q，WANG X，QIN Y，et al. SPOCD1 promotes the proliferation and metastasis o glioma cells by up-regulating PTX3[J]. Am J Cancer Res，2018，8（4）：624
[22] TAKEBE N，MIELE L，HARRIS P J，et al. Targeting notch，hedgehog，and wnt pathways in cancer stem cells： clinical update[J]. Nat Rev Clin Oncol，2015，12（8）：445

相似文献/References:

[1]朱悦,张诗武,张丹芳,等.TA2小鼠自发乳腺癌血清蛋白质组学研究[J].天津医科大学学报,2013,19(05):373.
[2]刘 营,孙保存,刘铁菊,等.AURKA蛋白激酶在三阴乳腺癌干细胞形成血管拟态中的实验研究[J].天津医科大学学报,2013,19(06):437.
　LIU Ying,SUN Bao-cun,LIU Tie-ju,et al.Experimental study of AURKA protein kinase in the formation of vascular mimicry in triple-negative breast cancer stem cells[J].Journal of Tianjin Medical University,2013,19(05):437.
[3]伦淑敏.HOXA5基因真核表达质粒的构建及在乳腺癌细胞中的功能研究[J].天津医科大学学报,2014,20(05):337.
　LUN Shu-min. Construction of HOXA5 eukaryotic expression plasmid of and its biological significance in breast cancer cells[J].Journal of Tianjin Medical University,2014,20(05):337.
[4]伦淑敏.肌细胞增强因子2A基因真核表达质粒的构建及对乳腺癌细胞MCF-7增殖能力的影响[J].天津医科大学学报,2014,20(06):429.
　LUN Shu-min.Construction of myocyte enhancer factor 2A eukaryotic expression plasmid and effects on cell proliferation in breast cancer cell line MCF7[J].Journal of Tianjin Medical University,2014,20(05):429.
[5]孙秀梅,张 飞,田 然,等.Nanog表达上调促进乳腺癌细胞MCF-7的增殖和侵袭[J].天津医科大学学报,2014,20(06):421.
　SUN Xiu-mei,ZHANG Fei,TIAN Ran,et al.Up-regulation of Nanog promotes cell proliferation and invasion in breast cancer cells MCF-7[J].Journal of Tianjin Medical University,2014,20(05):421.
[6]张 洁,张 飞,冀 为,等. SHP2不同突变体对乳腺癌细胞的迁移和侵袭能力的影响[J].天津医科大学学报,2015,21(02):93.
　ZHANG Jie,ZHANG Fei,JI Wei,et al. Effect of different SHP2 mutants on breast cancer cell migration and invasion[J].Journal of Tianjin Medical University,2015,21(05):93.
[7]蔡 隽. FOXQ1稳定表达乳腺癌细胞系的建立及鉴定[J].天津医科大学学报,2015,21(04):292.
　CAI Jun.Establishment and identification of cell lines with stable expression of FOXQ1 in MDA-MB-231-luc[J].Journal of Tianjin Medical University,2015,21(05):292.
[8]蔡 隽 综述,冯玉梅 审校.叉头框转录因子调控乳腺癌生物学特性的研究进展[J].天津医科大学学报,2015,21(05):455.
[9]任宗娜.沉默Notch4基因对乳腺癌细胞系MDA-MB-231增殖和迁移侵袭能力的影响[J].天津医科大学学报,2015,21(06):469.
　REN Zong-na.Inhibition effect of?silencing?? Notch4 gene on the proliferation and migration and invasion activity of? breast cancer cell line?MDA-MB-231[J].Journal of Tianjin Medical University,2015,21(05):469.
[10]周岩,宋伟杰,张飞,等.人附睾蛋白4在乳腺癌发生发展中的机制研究[J].天津医科大学学报,2015,21(06):466.
　ZHOU Yan,SONG Wei-jie,ZHANG Fei,et al.Mechanism of human epididymis protein 4 in development and progression of breast cancer[J].Journal of Tianjin Medical University,2015,21(05):466.
[11]赵雅雯,马勇杰.基于生物信息学分析PTX3基因在乳腺癌中的表达及临床意义[J].天津医科大学学报,2022,28(06):577.
　ZHAO Ya-wen,MA Yong-jie.Expression and clinical value of PTX3 gene in breast cancer based on bioinformatics analysis[J].Journal of Tianjin Medical University,2022,28(05):577.

备注/Memo

备注/Memo:

作者简介 贾圣陶（1996-），女，硕士在读，研究方向：生物化学与分子生物学；通信作者：马勇杰，E-mail：mayongjie@tjmuch.com。

常用功能

更新日期/Last Update: 2021-09-01